Public-private research partnerships
bioMérieux is involved in multidisciplinary research with academic centers and the international healthcare community.
For more than 15 years, bioMérieux and the Hospices Civils de Lyon (France) have been collaborating through an exceptional public-private research partnership. Two joint research laboratories within the Edouard Herriot and Lyon-Sud Hospitals in Lyon, France, are committed to performing research close to patients – combining medical expertise, academic research and diagnostic innovation in a truly original way.
The research program known as REALISM (REAnimation Low Immune Status Markers) was launched in October 2016. Led by BIOASTER (French Technology Innovation Institute in Study of microorganisms. bioMérieux uses culture-based microbiology methods for the growth of bacteria from biological fluids, food and pharmaceutical samples. The bacteria are subsequently identified and their susceptibility to antibiotics tested in certain cases.), bioMérieux, the College of Industrial Physics and Chemistry of the City of Paris (ESCPI), GSK, Lyon Civil Hospitals (HCL) and Sanofi, the program aims to identify and validate new promising biomarkers to improve the management of patients with a high risk of sepsis. The program also aims to develop predictive tests to enable personalized diagnostic and treatment strategies to prevent patients from developing sepsis. Personalizing patient management will reduce the risks of infectious complications and increase the patients’ chances of survival. This will also contribute to the fight against antimicrobial resistance: fewer infections will lead to less antibiotic prescriptions. The project was completed in 2018 and a first interpretation of the study results took place in 2019.
Within the framework of projects financed by the European Commission and led by IMI (Innovative Medicines Initiative), bioMérieux is a partner of the COMBACTE-CDI project (COMbatting BACTerial resistance in Europe), dedicated to Clostridiodes difficile is the main infectious cause of healthcare-associated diarrhea, and can lead to extremely serious and incapacitating pseudomembranous colitis. Due to its oral-fecal route of transmission and the persistence of spores on inert surfaces, C. difficile is highly contagious and requires drastic measures involving patient isolation, hygiene and disinfection. infections (CDI), which are among the most prevalent healthcare-associated infections. Launched in November 2017 for a 3-year period, this initiative aims to better understand the epidemiology and clinical impact of CDI in order to improve patient outcomes.
Together with the University of Antwerp and the Wellcome Trust, bioMérieux is coordinating the VALUE-Dx* project launched in April 2019 for a 4-year period. VALUE-Dx aims to assess and quantify the medical, economic, and public health value of diagnostics for optimizing use of antibiotics and combatting AMR.
* This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott Laboratories, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.
bioMérieux is also involved in the following European Consortiums.
(Innovative Training Networks)
Rapid point-of-care (POC) diagnostic tools play a key role in differentiating viral from bacterial infections, determining the optimal antibiotic therapy and ultimately the effective clinical management of patients with infectious diseases. As part of the European Commission’s Horizon 2020 – Research and Innovation Framework Programme, the “Nouveaux diagnostics pour les maladies infectieuses
(http://www.nd4id.eu/)” project offers students of different nationalities the opportunity to work in research labs to develop novel POC assays, targeting the most important and urgent clinical needs. bioMérieux is participating in this project by regularly taking on research students in its R&D facilities.
Better identify the cause of acute fever in children
bioMérieux is currently involved in two research partnerships to accelerate the identification of bacterial infections in children.
Personalized risk assessment for improved management of febrile children across Europe: rapid identification of bacterial infections in children
Personalized risk assessment for improved management of febrile children across Europe aims to address the problem of identifying bacterial infection and thus to reduce antibiotic misuse and AMR by developing better tests to distinguish bacterial from viral infection. The Personalized risk assessment for improved management of febrile children across Europe consortium includes 18 world renowned organizations, from 10 different countries, among which bioMérieux is the unique industrial partner. The Personalized risk assessment for improved management of febrile children across Europe grant is one of the largest awarded by the European Commission’s Horizon 2020 Health program in 2016 (€18 million) and aims, within a five-year period (2016-2021), to bring novel new diagnostics into clinical use and improve management of children presenting with high fever on arrival at a hospital or clinic. In 2020, following on from the Personalized risk assessment for improved management of febrile children across Europe project, the new DIAMONDS project has been awarded 22.5 million for the next five years and a rapid test to diagnose severe illnesses, using personalized gene signatures, is being developed by scientists at Imperial College London.
The BIOMARKERS TO DIFFERENTIATE BACTERIAL FROM VIRAL INFECTIONS project, which emerged as a result of collaboration between bioMérieux and the Hospices Civils de Lyon (France) aims to better identify the cause of acute fever in children. The large majority of infants under the age of 3 admitted to a Pediatric Emergency Department with fever of unknown origin (FUO) have a viral infection. Only 10 – 25% will have an infection of bacterial origin. Overestimation of bacterial infections results in broad-spectrum antibiotic therapy, which can contribute to the emergence of resistant bacteria. Research into specific biomarkers of these two types of infection in children will enable the differentiation of severe bacterial infections from viral infections and help to promote the appropriate use of antibiotics. At the end of 2019, the inclusion of a large cohort of nearly 1,000 children under 3 years of age hospitalized at HCL and other hospitals in France was finalized.
BIOMARKERS TO DIFFERENTIATE BACTERIAL FROM VIRAL INFECTIONS: diagnosing severe bacterial infections in children
Dr Marine Butin’s point of view
Dr. Marine Butin, MD, PhD
Neonatal Resuscitation Department – Hôpital Femme Mère Enfant – Hospices Civils de Lyon (France)
International Center for Infectiology Research
Staphylococcal pathogenesis team
INSERM U1111 – CNRS UMR5308 – ENS Lyon – Université de Lyon (France)
“In neonatal resuscitation departments, infections are a common occurrence, owing to the extreme vulnerability of the patients and the high number of invasive procedures (catheters, intubation, etc.) which increase the risk of infection. The use of antibiotics is therefore frequent and necessary, yet at times, they may be misused and overused. The unnecessary administration of antibiotics may have severe consequences for the patient and for the microbial ecology of the department.
Aside from the obvious toxicity of certain antibiotics and the effects on the patient’s intestinal flora, the use of antibiotics can also contribute to the emergence of antimicrobial resistance. Recently, in neonatal resuscitation departments, we have had occurrences of infections caused by multiresistant bacteria, for which we have only a limited number of treatment options, and the use of last resort antibiotics has not been extensively studied in newborns.
The prudent use of antibiotics is therefore a major challenge in our day-to-day practices.”
Global Point Prevalence Survey
The Global Point Prevalence Survey* (GLOBAL-PPS) is a study uniquely supported by bioMérieux, which originated at the 4th World HAI/Resistance Forum World HAI/Resistance Forum in 2013. The Global-PPS was launched in 2014 and was designed to provide a global “snapshot” of antibiotic use and resistance in hospitals. The GLOBAL-PPS has been endorsed by World Health Organization, The Center for Disease Dynamics, Economics & Policy, Infectious Diseases Society of America and Global Antibiotic Resistance Partnership.
> Watch the video of the Global-PPS
Unprecedented in scope, it is coordinated by the University of Antwerp Hospital (Belgium) and a group of experts including Professors Herman Goossens, Dilip Nathwani, Vincent Jarlier and Peter Zarb, who have already conducted studies of this kind. In the first edition in 2015, it included 100,000 patients and mobilized more than 335 hospital centers in more than 53 countries across all continents. The information obtained will be used to create a global database dedicated to antibiotic consumption and resistance in hospital settings. The results of the survey were presented during European Congress of Clinical Microbiology and Infectious Diseases 2016. (http://www.global-pps.com/dissemination)
Following the valuable insights obtained through the first GLOBAL-PPS, bioMérieux renewed its support for a second edition of this survey in 2017, which places more emphasis on education and on low- and middle-income countries (Low and Middle Income Countries), which frequently have high antimicrobial prescription rates and resistance levels, yet have no access to surveillance networks. The GLOBAL-PPS now involves over 900 hospitals and over 200,000 patients in 90 countries. It offers educational tools, in particular a PPS e-learning tool developed by the British Society for Antimicrobial Chemotherapy with bioMérieux’s support. This training module, associated with other tools, will help hospitals develop and implement customized action plans based on their Global-PPS results and local priorities.
> Discover the latest results, published in the journal Lancet Global Health: Lancet Global Health Main Article GLOBAL-PPS
* bioMérieux, as part of its global commitment to surveillance and stewardship, is the sole sponsor of the GLOBAL-PPS and E-learning PPS. bioMérieux has no role in study design, data collection, data analysis, data interpretation, or writing the report. Data are strictly confidential and stored anonymously at the coordinating centre of the University of Antwerp, Belgium.
Furthermore, bioMérieux research teams work in ever-closer cooperation with pharmaceutical companies to develop susceptibility tests to accompany the launch of new antibiotics on the market. The bioMérieux Companion Diagnostic program offers tailored and complete partnerships with pharmaceutical companies, which includes:
- implementing a supportive diagnostic approach during the clinical trials of a novel antibiotic by targeting the optimal patient population and pathogens, leading to both time- and cost- savings for pharmaceutical companies, as well as an increased probability of trial success.
- developing a “companion diagnostic” test that could be used during the antibiotic commercialization step to ensure the most appropriate choice of antibiotic in a given context (i.e. “Personalized Medicine ”).
As part of its ongoing collaboration with AstraZeneca*, a global, science-led biopharmaceutical company, bioMérieux is supporting their iCREST multicenter surveillance study. iCREST: The infection-Carbapenem Resistance Evaluation Surveillance Trial The project will make use of bioMérieux’s CHROMID® CARBA SMART chromogenic culture media and 2 types of bioMérieux’s antibiotic susceptibility strips (ETEST®). The objective is to determine the prevalence of carbapenem-resistant infections and to assess the efficiency of a new combination antibiotic, Zavicefta/Avicaz (ceftazidime/avibactam) to treat these serious antibiotic-resistant infections.
Carbapenem resistance is classified by Centers for Disease Control and Prevention and Prevention as “an immediate public health threat that requires urgent and aggressive action Antibiotic Resistance Threats in the United States, CDC 2013, and is also a critical issue in The Priority Pathogens List published by WHO to promote the development of new antibiotic. (http://www.who.int/medicines/areas/rational_use/prioritization-of-pathogens/en/)
* Due to the acquisition of AstraZeneca’s anti-infective business by Pfizer, moving forward, this program will be managed by Pfizer.